GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (OTCPK:HOPHF) » Definitions » 3-Year EPS without NRI Growth Rate

Hemogenyx Pharmaceuticals (Hemogenyx Pharmaceuticals) 3-Year EPS without NRI Growth Rate : -6.30% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Hemogenyx Pharmaceuticals 3-Year EPS without NRI Growth Rate?

Hemogenyx Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2023 was $-0.00.

During the past 3 years, the average EPS without NRI Growth Rate was -6.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 9 years, the highest 3-Year average EPS without NRI Growth Rate of Hemogenyx Pharmaceuticals was -6.30% per year. The lowest was -20.50% per year. And the median was -10.10% per year.


Competitive Comparison of Hemogenyx Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemogenyx Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



Hemogenyx Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Hemogenyx Pharmaceuticals  (OTCPK:HOPHF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Hemogenyx Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemogenyx Pharmaceuticals (Hemogenyx Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.